BRCA-P: An international randomised phase III study evaluating the RANK ligand inhibitor denosumab for the prevention of breast cancer in BRCA1 mutation carriers [ 2018 - 2022 ]

Research Grant

Researchers: Prof Geoffrey Lindeman (Principal investigator) ,  A/Pr Prudence Francis ,  Prof Christobel Saunders ,  Prof Gregory Mann ,  Prof Kelly-Anne Phillips

Brief description Women with a faulty BRCA1 gene are at high lifetime risk for breast cancer. Identifying a safe and effective prevention therapy is therefore a ‘holy grail’. We have discovered that denosumab, used to treat osteoporosis or breast cancer spread to bone, could be ‘repurposed’ as a prevention drug. BRCA-P is an international randomised controlled study that will determine if denosumab prevents breast cancer. Associated translational research will facilitate swift transfer to the clinic.

Funding Amount $AUD 2,625,295.59

Funding Scheme Project Grants

Notes Standard Project Grant